Donepezil eliminates suppressive effects of β-amyloid peptide (1-42) on long-term potentiation in the hippocampus.
β-Amyloid peptide 1-42 in a concentration of 200 nM impairs induction of long-term posttetanic potentiation of population spike in CA1 pyramidal neurons in rat hippocampal slices. Application of donepezil, a drug used for the treatment of Alzheimer disease, in a concentration of 1 μM eliminates the suppressive effect of β-amyloid peptide 1-42 on long-term posttenanic potentiation in the hippocampus.
Research Center of Neurology, Russian Academy of Medical Sciences, Moscow, Russia.
N A
NA
Kapai
E I
EI
Solntseva
V G
VG
Skrebitskii
D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D000077265:Donepezil; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology*; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010446:Peptide Fragments / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric
D016229:Amyloid beta-Peptides; D007189:Indans; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D010880:Piperidines; C075222:amyloid beta-protein (1-42); D000077265:Donepezil